Cetuximab
What's New
Last Posted: Dec 21, 2020
- Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Jensen Benny V et al. International journal of cancer 2020 Dec - Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher Julie G et al. Targeted oncology 2020 Oct - Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
Summers Matthew G et al. European journal of cancer (Oxford, England : 1990) 2020 12456-63 - Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz Heinz-Josef et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 37(22) 1876-1885 - How to Apply Supervised Machine Learning Tools to MS Imaging Files: Case Study with Cancer Spheroids Undergoing Treatment with the Monoclonal Antibody, Cetuximab.
Hua David et al. Journal of the American Society for Mass Spectrometry 2020 May - Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.
Freml Jared et al. Personalized medicine 2020 Apr - Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives.
Martinelli E et al. Annals of oncology : official journal of the European Society for Medical Oncology 2020 Jan 31(1) 30-40 - Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.
Di Nardo Lucia et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2019 Nov - Precision treatment in colorectal cancer: Now and the future.
Yau Tung On et al. JGH open : an open access journal of gastroenterology and hepatology 2019 Oct 3(5) 361-369 - Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb Julien et al. JAMA oncology 2018 4(7) e173695
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
- NIH Information (1)
- Human Genome Epidemiologic Studies (410)
- GWAS Studies (2)
- Human Genomics Translation/Implementation Studies (23)
- Genomic Tests Evidence Synthesis (3)
- Genomic Tests Guidelines (5)
- Tier-Classified Guidelines (3)
- Non-Genomics Precision Health (1)
- Reviews/Commentaries (13)
- Tools/Methods (1)
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 26, 2021
- Content source: